Tissue Bank Pays Dividends for Brain Cancer Research
Complete the form below to unlock access to ALL audio articles.
Dr Jodi Saunus and Professor Sunil Lakhani from theUQ Centre for Clinical Research have worked with rare metastatic brain tumour samples to discover genetic information that could lead to new cancer treatments.
Metastatic brain tumours − cancers that have spread to the brain from another tumour – are currently incurable, with life expectancy ranging from a few months to a few years after diagnosis.
Dr Saunus said their study was the first of its kind to use genome sequencing to examine a cohort of secondary brain tumours.
“This study deepens our understanding of secondary brain tumours and highlights opportunities for new drug targets,” she said.
“We have identified particular genes and inter-related networks of genes linked to the development of brain metastases.
“We have also found potential drug targets in a large proportion of the tumours, including a molecule called HER3 that we had already been investigating.”
Dr Saunus said new treatment options for metastatic brain cancer patients were desperately needed.
“Identifying new targets could have a huge impact on fighting this disease, as it lays a foundation for the development of new treatments,” she said.
“With the incidence of brain metastases increasing, the burden of this complication is now greater than any individual cancer type.
“Despite being responsible for most cancer-related deaths and illness, secondary cancers are not a current focus of large-scale cancer genome sequencing studies.
“However, with increasing development of more effective cancer treatments, there could be new opportunities to explore.”
Dr Saunus said the discoveries would not have been possible without the valuable samples provided by the Brisbane Breast Bank, as metastatic brain cancer tissue samples were not easy to come by.
She said the research team anticipated the data from the study would be more extensively analysed by the international research community.
Researchers worked in collaboration with Pathology Queensland, UQ’s Institute for Molecular Bioscience, theQIMR Berghofer Medical Research Institute and the Royal Brisbane and Women’s Hospital.
